4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Yu Fang, Zou Xiang. Roles and relevance of mast cells in infection and vaccination[J]. The Journal of Biomedical Research, 2016, 30(4): 253-263. DOI: 10.7555/JBR.30.20150038
Citation: Yu Fang, Zou Xiang. Roles and relevance of mast cells in infection and vaccination[J]. The Journal of Biomedical Research, 2016, 30(4): 253-263. DOI: 10.7555/JBR.30.20150038

Roles and relevance of mast cells in infection and vaccination

Funds: 

This work was supported by Stiftelsen Clas Groschinskys Minnesfond

Konsul Berghs Stiftelse, Sweden. YF was supported by a postdoctoral start-up grant from the Affiliated Hospital of Guizhou Medical University, Guiyang, China.

More Information
  • Received Date: February 25, 2015
  • Revised Date: April 07, 2015
  • In addition to their well-established role in allergy mast cells have been described as contributing to functional regulation of both innate and adaptive immune responses in host defense. Mast cells are of hematopoietic origin but typically complete their differentiation in tissues where they express immune regulatory functions by releasing diverse mediators and cytokines. Mast cells are abundant at mucosal tissues which are portals of entry for common infectious agents in addition to allergens. Here, we review the current understanding of the participation of mast cells in defense against infection. We also discuss possibilities of exploiting mast cell activation to provide adequate adjuvant activity that is needed in high-quality vaccination against infectious diseases.
  • Related Articles

    [1]Zhaoye Qian, Zhe Zhang, Lanqi Cen, Yaohua Ke, Jie Shao, Manman Tian, Baorui Liu. Mycobacterium smegmatis enhances shikonin-induced immunogenic cell death—an efficient in situ tumor vaccine strategy[J]. The Journal of Biomedical Research, 2024, 38(4): 369-381. DOI: 10.7555/JBR.38.20240049
    [2]Brianna Lide, Shane McGuire, Hong Liu, Cristina Chandler. Mast cell activation syndrome—anesthetic challenges in two different clinical scenarios[J]. The Journal of Biomedical Research, 2022, 36(6): 435-439. DOI: 10.7555/JBR.36.20220071
    [3]Liu Zhi, Wang Jianwei, Ge Yiyue, Xu Yuyu, Guo Mengchen, Mi Kai, Xu Rui, Pei Yang, Zhang Qiankun, Luan Xiaoting, Hu Zhibin, Chi Ying, Liu Xingyin. SARS-CoV-2 encoded microRNAs are involved in the process of virus infection and host immune response[J]. The Journal of Biomedical Research, 2021, 35(3): 216-227. DOI: 10.7555/JBR.35.20200154
    [4]Mehta Neha, Qiao Renli. Medical management of COVID-19 clinic[J]. The Journal of Biomedical Research, 2020, 34(6): 416-421. DOI: 10.7555/JBR.34.20200118
    [5]Tao Chun'ai, Gan Yongxin, Su Weidong, Li Zhutian, Tang Xiaolan. Effectiveness of hospital disinfection and experience learnt from 11 years of surveillance[J]. The Journal of Biomedical Research, 2019, 33(6): 408-413. DOI: 10.7555/JBR.33.20180118
    [6]Vijayakumar Subramaniyan, Ramesh Venkatachalam, Prabhu Srinivasan, Manogar Palani. In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever[J]. The Journal of Biomedical Research, 2018, 32(3): 222-236. DOI: 10.7555/JBR.31.20160109
    [7]Sukhbir Kaur, Tejinder Kaur, Jyoti Joshi. Immunogenicity and protective efficacy of DNA vaccine against visceral leishmaniasis in BALB/c mice[J]. The Journal of Biomedical Research, 2016, 30(4): 304-313. DOI: 10.7555/JBR.30.20150125
    [8]Joshua Muli Mutiso, John Chege Macharia, Maria Ndunge Kiio, James Maina Ichagichu, Hitler Rikoi, Michael Muita Gicheru. Development of Leishmania vaccines: predicting the future from past and present experience[J]. The Journal of Biomedical Research, 2013, 27(2): 85-102. DOI: 10.7555/JBR.27.20120064
    [9]Joshua Muli Mutiso, John Chege Macharia, Evans Taracha, Michael Muita Gicheru. Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops)[J]. The Journal of Biomedical Research, 2012, 26(1): 8-16. DOI: 10.1016/S1674-8301(12)60002-5
    [10]Joshua M. Mutiso, John C. Macharia, Michael M. Gicheru. A review of adjuvants for Leishmania vaccine candidates[J]. The Journal of Biomedical Research, 2010, 24(1): 16-25.
  • Cited by

    Periodical cited type(7)

    1. Li M, Ning P, Bai R, et al. DNA Methylation Negatively Regulates Gene Expression of Key Cytokines Secreted by BMMCs Recognizing FMDV-VLPs. Int J Mol Sci, 2024, 25(19): 10849. DOI:10.3390/ijms251910849
    2. Volpedo G, Pacheco-Fernandez T, Bhattacharya P, et al. Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development. Front Immunol, 2021, 12: 748325. DOI:10.3389/fimmu.2021.748325
    3. Korkmaz E, Balmert SC, Sumpter TL, et al. Microarray patches enable the development of skin-targeted vaccines against COVID-19. Adv Drug Deliv Rev, 2021, 171: 164-186. DOI:10.1016/j.addr.2021.01.022
    4. Zhu W, Dong C, Wei L, et al. Promising Adjuvants and Platforms for Influenza Vaccine Development. Pharmaceutics, 2021, 13(1): 68. DOI:10.3390/pharmaceutics13010068
    5. Tong X, Chen S, Zheng H, et al. Increased IL-27/IL-27R expression in association with the immunopathology of murine ocular toxoplasmosis. Parasitol Res, 2018, 117(7): 2255-2263. DOI:10.1007/s00436-018-5914-7
    6. Appel K, Munoz E, Navarrete C, et al. Immunomodulatory and Inhibitory Effect of Immulina®, and Immunloges® in the Ig-E Mediated Activation of RBL-2H3 Cells. A New Role in Allergic Inflammatory Responses. Plants (Basel), 2018, 7(1): 13. DOI:10.3390/plants7010013
    7. Yoshino N, Takeshita R, Kawamura H, et al. Mast cells partially contribute to mucosal adjuvanticity of surfactin in mice. Immun Inflamm Dis, 2018, 6(1): 117-127. DOI:10.1002/iid3.204

    Other cited types(0)

Catalog

    Article Metrics

    Article views (3335) PDF downloads (520) Cited by(7)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return